Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Status: Closed to Accrual

Learn more:

• clinicaltrials.gov: #NCT03528408
• See news release

Abstracts/Posters/Presentations:

• S Rapisuwon, SP Patel, RD Carvajal, LF Hernandez-Aya, K Tsai, S Chandra, MT Tan, A Daud, JA Sosman, MB Atkins. Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma. Accepted to the 16th International Congress of the Society for Melanoma Research, Nov. 20-23, 2019, Salt Lake City, Utah. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.